These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36407950)

  • 1. Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.
    Pagare PP; Obeng S; Huang B; Marcus MM; Nicholson KL; Townsend AE; Banks ML; Zhang Y
    ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1197-1209. PubMed ID: 36407950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
    Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
    Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
    Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y
    Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
    Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.
    Altarifi AA; Yuan Y; Zhang Y; Selley DE; Negus SS
    Psychopharmacology (Berl); 2015 Feb; 232(4):815-24. PubMed ID: 25178814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
    Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
    Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
    Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
    Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
    Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
    Wang H; Reinecke BA; Zhang Y
    J Comput Aided Mol Des; 2020 Aug; 34(8):879-895. PubMed ID: 32193867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
    Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
    Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Huang P; Ho CK; Cao D; Inan S; Rawls SM; Li M; Huang B; Pagare PP; Townsend EA; Poklis JL; Halquist MS; Banks M; Zhang Y; Liu-Chen LY
    J Pharmacol Exp Ther; 2024 Feb; 389(1):106-17. PubMed ID: 38409113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor.
    Siemian JN; Obeng S; Zhang Y; Zhang Y; Li JX
    J Pharmacol Exp Ther; 2016 Jun; 357(3):509-19. PubMed ID: 27056847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
    Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
    ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.
    Pagare PP; Li M; Zheng Y; Kulkarni AS; Obeng S; Huang B; Ruiz C; Gillespie JC; Mendez RE; Stevens DL; Poklis JL; Halquist MS; Dewey WL; Selley DE; Zhang Y
    J Med Chem; 2022 Mar; 65(6):5095-5112. PubMed ID: 35255685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.
    Yuan Y; Li G; He H; Stevens DL; Kozak P; Scoggins KL; Mitra P; Gerk PM; Selley DE; Dewey WL; Zhang Y
    ACS Chem Neurosci; 2011 Jul; 2(7):346-51. PubMed ID: 22816021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.
    Moerke MJ; Negus SS
    Neuropharmacology; 2019 Jun; 151():180-188. PubMed ID: 30880123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.
    Sadee W; McKew JC
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.